

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Formerly known as 培力控股有限公司 in Chinese)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

**CHANGE OF COMPANY NAME
CHANGE OF STOCK SHORT NAME ON THE STOCK EXCHANGE
AMENDMENTS TO THE MEMORANDUM
AND ARTICLES OF ASSOCIATION OF THE COMPANY**

References are made to the announcement of PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 21 April 2021, the circular of the Company dated 22 April 2021 (the “**Circular**”) and the announcement of the Company dated 28 May 2021 in relation to the poll results of the Annual General Meeting (the “**AGM**”). Unless otherwise specified, the capitalised terms used herein shall have the same meaning as those defined in the Circular.

CHANGE OF COMPANY NAME

The board of directors (“**Board**”) of the Company is pleased to announce that subsequent to the passing of the special resolution at the AGM in relation to the Change of Company Name, the Company has changed its dual foreign name in Chinese from “培力控股有限公司” to “培力農本方有限公司”.

The Certificate of Incorporation on Change of Name was issued by the Registrar of Companies in the Cayman Islands on 6 July 2021, and the Certificate of Registration of Alteration of Name of Registered Non-Hong Kong Company was issued by the Registrar of Companies in Hong Kong on 29 July 2021.

CHANGE OF STOCK SHORT NAME ON THE STOCK EXCHANGE

The Chinese stock short name of the Company for trading in the Shares on the Stock Exchange will be changed from “培力控股” to “培力農本方” with effect from 9:00 a.m. on 13 August 2021. The stock code of the Company remains unchanged as “1498” and other trading arrangements in relation to the Company will remain unchanged.

AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION

The Board is also pleased to announce that the special resolutions amending the Articles in relation to the means of receipt of the corporation communication and the proposed Change of Company Name were registered by the Companies Registrar of the Cayman Islands on 6 July 2021, and the Articles were amended accordingly.

EFFECTS OF THE CHANGE OF COMPANY NAME

The proposed Change of Company Name will not affect any rights of the existing holders of Shares nor the Company’s daily business operation and its financial position. All the existing share certificates of the Company in issue bearing the existing name of the Company will, after the Change of Company Name being effective, continue to be evidence of title to such Shares and will continue to be valid for trading, settlement, registration and delivery of such Shares. There will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates printed in the new names of the Company. With effect from 13 August 2021, any new share certificates will be issued under the Company’s new name.

By Order of the Board
PuraPharm Corporation Limited
(Formerly known as 培力控股有限公司 in Chinese)
Chan Yu Ling, Abraham
Chairman and Executive Director

Hong Kong, 9 August 2021

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; the non-executive Directors of the Company are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.